Kyowa Kirin Co., Ltd., Tokyo 100-0004, Japan.
Molecular Neuropharmacology Laboratory, Wenzhou Medical University, Wenzhou 325015, China.
Molecules. 2022 Apr 6;27(7):2366. doi: 10.3390/molecules27072366.
The adenosine A receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson's disease (PD). The selective A receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to levodopa/decarboxylase inhibitors in adults with PD experiencing OFF episodes or a wearing-off phenomenon; however, the full potential of this drug class remains to be explored. In this article, we review the pharmacology of adenosine A receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification.
腺苷 A 受体亚型被认为是治疗神经退行性疾病（尤其是帕金森病）的非多巴胺能药物靶点。选择性 A 受体拮抗剂伊曲茶碱在美国和日本被批准作为左旋多巴/脱羧酶抑制剂的辅助治疗药物，用于治疗出现“OFF”发作或“关期”现象的成年帕金森病患者；然而，这类药物的全部潜力仍有待探索。本文从治疗帕金森病的运动和非运动症状及其对疾病修饰的潜在作用的角度，综述了腺苷 A 受体拮抗剂的药理学。
